Plain-English translation of NCT06847542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way to deliver , a medication that helps slow vision loss from wet age-related macular degeneration. Instead of getting frequent eye injections, participants receive a tiny implant placed surgically in the eye that slowly releases the medication over several months. The study will measure whether this implant works well, is safe, and improves patients' quality of life compared to traditional injection schedules.
Patients with wet age-related macular degeneration currently need frequent eye injections—sometimes monthly—to keep their vision stable. This trial exists to see whether a longer-lasting implant could reduce the burden of frequent clinic visits while still protecting eyesight effectively.
You likely qualify if…
You likely don't qualify if…
You will undergo outpatient eye surgery to have the implant placed in your study eye on Day 1. Over the following 36 weeks (about 9 months), you will have multiple follow-up visits so doctors can monitor how well the implant is working and check for any side effects. Depending on how your eye responds, you may receive refill exchanges (a procedure to replenish the medication in the implant) every 24 or 36 weeks. Throughout the study, researchers will measure your vision, take images of your eye, and ask you about your symptoms and quality of life.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
Austria
Czechia